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Nitric oxide (NO) has long been recognized as a multifaceted participant in brain physiology. Despite the knowledge that was
gathered over many years regarding the contribution of NO to neuronal plasticity, for example the ability of the brain to
change in response to new stimuli, only in recent years have we begun to understand how NO acts on the molecular and
cellular level to orchestrate such important phenomena as synaptic plasticity (modification of the strength of existing
synapses) or the formation of new synapses (synaptogenesis) and new neurons (neurogenesis). Post-translational modification
of proteins by NO derivatives or reactive nitrogen species is a non-classical mechanism for signalling by NO. S-nitrosation is a
reversible post-translational modification of thiol groups (mainly on cysteines) that may result in a change of function of the
modified protein. S-nitrosation of key target proteins has emerged as a main regulatory mechanism by which NO can
influence several levels of brain plasticity, which are reviewed in this work. Understanding how S-nitrosation contributes to
neural plasticity can help us to better understand the physiology of these processes, and to better address pathological
changes in plasticity that are involved in the pathophysiology of several neurological diseases.
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Introduction
Brain plasticity is regarded as the ability of the brain to
change its structure and function as a result of experience and
changes in environment. Plasticity occurs mostly at three
different levels: modification of the strength of existing syn-
apses (synaptic plasticity), formation of new synapses (syn-
aptogenesis) and formation of new neurons (neurogenesis).
Many factors, including nitric oxide (NO), regulate and fine-
tune these mechanisms.
Synaptic plasticity is described as the change in strength
of a synapse in response to changes in synaptic activity.
Short-term plasticity occurs on a scale from milliseconds to
minutes, and is often associated with changes in the pres-
ynaptic release of neurotransmitters. Longer forms of plas-
ticity occur in the postsynaptic terminal, such as long-term
potentiation (LTP) or depression (LTD); initial changes (in
the first 1 or 2 h) in LTP or LTD are associated with altera-
tions in the trafficking of glutamate receptors, while main-
tenance of LTP and LTD for longer periods requires changes
in gene expression. The increase in postsynaptic strength is
triggered by activation of NMDA receptors, which causes
calcium influx into the postsynaptic cell and activates signal
transduction pathways that result in insertion in the mem-
brane of a different type of glutamate receptors, AMPA
receptors. The regulation of membrane insertion of AMPA
receptors is key for efficient synaptic plasticity, and a large
body of evidence can be found regarding the control of
AMPA receptor trafficking (see Ho et al., 2011b), including
by NO.
Synaptogenesis refers not only to formation of new syn-
apses, but also to the remodelling of existing ones. Synapse
formation occurs during development and in the adult
brain, and may be changed by experience or disease (see
Pérez-Domper et al., 2013; Robichaux and Cowan, 2014). NO
has been consistently involved in such a rearrangement of
existing synapses and formation of new ones (García-López
et al., 2010; Shelly et al., 2010; Sunico et al., 2010).
Neurogenesis is not restricted to embryonic development,
but occurs throughout adult life. New neurons and glial cells
are continuously formed in the brain, from neural stem cells
present in niches such as the subventricular zone and the
dentate gyrus in the hippocampus (see Gage and Temple,
2013). Neurogenesis is a tightly regulated process, and NO is
one of the many factors that influence the formation of new
brain cells in physiological conditions and in disease states
(see Carreira et al., 2012; Estrada and Murillo-Carretero,
2005).
In the brain, the free radical gaseous messenger NO is
associated with the regulation of neuronal plasticity and cog-
nitive functions, and also regulates biological functions such
as the sleep-wake cycle, body temperature, appetite and
hormone release, and modulates neuronal development,
nociception and apoptosis (see Calabrese et al., 2007; Prast
and Philippu, 2001). NO is mainly produced by nitric oxide
synthases (NOS), which can be found in the CNS in three
different isoforms: (i) neuronal NOS (nNOS or NOS1), which
is constitutively expressed in neurons; (ii) endothelial NOS
(eNOS or NOS3), constitutively expressed in endothelial cells;
and (iii) inducible NOS (iNOS or NOS2), which is mainly
expressed by activated microglial cells. While nNOS and
eNOS are constitutively expressed and are transiently acti-
vated by calcium/calmodulin and other regulators, iNOS is
transcriptionally regulated by inflammation or toxic stimuli
and its activity is independent of calcium regulation (Bredt,
1999; Guix et al., 2005).
The potential of NO as a modulator of synaptic transmis-
sion was first proposed in 1988 (Garthwaite et al., 1988), and
its presence was documented in several brain regions such as
the hippocampus, striatum, hypothalamus and locus coer-
uleus (Prast and Philippu, 2001). The small size of NO, its
highly diffusible nature and its link to glutamate receptors
make NO a special neurotransmitter. NO may be considered
an atypical neurotransmitter, as it does not require vesicle
storage or exocytotic release, being produced generally after
receptor activation and readily diffused throughout cells and
tissues. NO also modulates the release of several neurotrans-
mitters such as acetylcholine, catecholamines, glutamate and
GABA (see Prast and Philippu, 2001). NO is able to mediate
both postsynaptic intracellular signalling and retrograde
intercellular communication between different types of cells
and tissues. However, the short half-life of NO and its diffu-
sion coefficient (2.2 × 10−5 cm2 s−1 obtained in vivo) limit the
range of action of NO in brain tissue, thus providing short-
range responses in individual synapses (Santos et al., 2011;
Martínez-Ruiz et al., 2013).
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Classical NO signalling proceeds through its potent
binding to soluble guanylate cyclase (sGC), which activates
this enzyme that produces cyclic GMP (cGMP). cGMP in turn
reacts with a family of cGMP-dependent protein kinases (also
called PKG), triggering several signalling pathways (see
Hofmann, 2005; Francis et al., 2010). A less classical mode of
action of NO is through interaction with mitochondrial pro-
teins, especially inhibition of cytochrome c oxidase. Non-
classical NO signalling includes both the production of NO
from alternative sources (mainly nitrite) and the formation of
covalent post-translational modifications (PTM) in proteins
(see Martínez-Ruiz et al., 2011). These PTM are not formed by
NO itself, but by the production of the so-called reactive
nitrogen species (RNS), small molecules produced from NO
reactions. Although there are several RNS-induced PTM, three
of them have been more intensively studied. Tyrosine nitra-
tion, the incorporation of a nitro group (−NO2) to a tyrosine
residue, is considered an almost irreversible modification,
so it has been related to protein damage, although it is
also implied in signalling pathways (Souza et al., 2008;
Ischiropoulos, 2009). Cysteine S-glutathionylation, the for-
mation of a mixed disulfide between a protein cysteine thiol
and glutathione, is a reversible modification whose formation
and removal may be mediated by enzymes such as glutar-
edoxins. It has been involved in cell signalling and in oxida-
tive stress, it can be formed from either reactive oxygen
species or RNS, and it is related to S-nitrosation in several
ways, including the fact that S-nitrosation of a cysteine
residue or of glutathione can lead to S-glutathionylation (see
Martínez-Ruiz and Lamas, 2007; Mieyal et al., 2008; Sabens
Liedhegner et al., 2012).
Protein S-nitrosation is the formation of a nitrosothiol
(R-S-NO) in cysteine residues (denoted PSNO). It is also called
S-nitrosylation (the terminology has been discussed in
Martínez-Ruiz and Lamas, 2004; Heinrich et al., 2013), and
both names could be used for the overall description of the
PTM, as their difference relies mainly in the chemical mecha-
nisms for their formation, which is not always known or
considered (Heinrich et al., 2013). We will follow the recent
recommendation in this Journal to use the term S-nitrosation
as it includes the most part of the cases and can induce less
confusion (Heinrich et al., 2013). Nitrosothiols are not
formed from the direct reaction of NO with the cysteine
residue, unless it is in the thiyl radical form (P-S•).
P-S NO P-S-NO• + • →
There are several chemical mechanisms that can lead to
protein S-nitrosation, including formation of N2O3,
2 22 2NO O NO+ →
NO NO N O2 2 3+ →
a species that is a very effective nitrosating agent.
N O PSH PSNO H NO2 3 2+ → + ++ −
Nitrosothiols are not very stable in the cells compared with
other PTM because of the lability of the bond, the presence
of denitrosylases and other reductants (e.g. ascorbate), and
the easy reaction with other thiols to transfer the nitroso
group to either low molecular mass thiols or proteins
(transnitrosation)
PSNO RSH PSH RSNO+ → +
PSNO P SH PSH P SNO+ ′ → + ′
or to produce a mixed disulfide, leading to S-thiolation or
S-glutathionylation.
PSNO RSH PSSR HNO S-thiolation RSH is a low
molecular mass 
+ → + ( :
thiol)
PSNO GSH PSSG HNO S-glutathionylation GSH is
glutathione
+ → + ( :
).
Enzymic catalysis is not strictly necessary for its formation
and degradation in cell environment, so its specificity and
involvement in cell signalling bears some properties that
make it different from other signalling PTM such as phospho-
rylation (see Martínez-Ruiz and Lamas, 2004; Martínez-Ruiz
et al., 2011). Because of some of these properties, we have
proposed that it is mainly used by cells as a short-range
NO-derived signalling mechanism that can be favoured in
proteins located at a short distance from the sources of NO,
namely NOS, and in proteins interacting with them
(Martínez-Ruiz et al., 2013).
In this work, we review the role of S-nitrosation and
other NO signalling pathways in neuronal plasticity. The
S-nitrosated proteins discussed in this review are summarized
in Table 1.
S-nitrosation in synaptic plasticity
Synaptic plasticity refers essentially to the modification of the
synaptic response upon intense or decreased synaptic input
at a given synapse, resulting in long-lasting potentiation or
depression of the synaptic function (see Ho et al., 2011b;
Choquet and Triller, 2013). Both presynaptic and postsynap-
tic changes in synaptic function can occur, but for the
purpose of this review, we will focus on postsynaptic altera-
tions of synaptic strength. The presynaptic modulation of
synaptic plasticity by NO has been the focus of a recent
comprehensive review (Hardingham et al., 2013) and will not
be discussed here. The changes in synaptic strength can be
achieved by different mechanisms in different synapses
throughout the brain. In the hippocampus, for instance, glu-
tamate release and glutamate receptors are generally associ-
ated with LTP, and LTP is achieved by altering the number of
AMPA receptors on the postsynaptic membrane. More recep-
tors activated each time glutamate is released means a sus-
tained larger excitatory postsynaptic potential (EPSP), while
the opposite (fewer AMPA receptors on the post synaptic
membrane) holds true for LTD. LTP is usually expressed by a
larger amplitude in EPSP following a high-frequency stimu-
lation, while LTD is characterized by a decrease in the ampli-
tude of EPSP after low-frequency stimulation. LTP can be
dependent on NMDA receptors, which are fundamental for
modifying synaptic strength in the initial stages of LTP, as
they trigger the signalling pathways that result in the mobi-
lization of more AMPA receptors towards the postsynaptic
membrane (Bliss and Collingridge, 2013). NMDA-
independent mechanisms for LTP are also characterized
(Oren et al., 2009), but will not be discussed in this work. The
mechanism for LTD induction may involve also NMDA
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receptors in some brain regions, such as the hippocampus,
while metabotropic glutamate receptors are involved in LTD
induction in the cerebellum, for instance. Thus, the mecha-
nism for LTP or LTD is region- and synapse-specific. For the
purpose of this review, we will focus on NMDA receptor-
dependent potentiation of synaptic activity.
Physiologically, the activation of NMDA receptors results
in calcium influx through the receptor channel. To induce
LTP, calcium will activate PKs, such as calcium/calmodulin-
dependent PK II (CaMKII), which will phosphorylate AMPA
receptors present in postsynaptic pools of vesicles, making
them insert into the postsynaptic membrane (see Ho et al.,
2011b). Phosphorylation of AMPA receptors by CaMKII and
other kinases will also increase channel conductance and
opening probability (Lee et al., 2000; 2010). The calcium
influx via NMDA receptors that triggers LTP is also coupled to
the postsynaptic synthesis of NO, given the close proximity
of nNOS with NMDA receptors because of the interaction
with the scaffolding postsynaptic density protein 95 (PSD-95)
(Sattler et al., 1999). The small distance between nNOS and
the NMDA receptor allows the production of NO when
calcium enters the postsynaptic neuron directly through the
Table 1
Proteins modified by S-nitrosation that contribute to brain plasticity
Protein
S-nitrosated
Cys Functional significance Experimental context References
NSF Cys91 Increase of membrane insertion of AMPA
receptors GluA2 subunits
NO donors increase NSF-GluA2
association; impairment of GluA2
surface expression in nNOS-deficient
mice
Huang et al.,
2005
Stargazin Cys3 Up-regulation of AMPA receptors in the
nucleus accumbens
NO donors elicit S-nitrosation of
stargazin
Selvakumar
et al., 2009
GluA1 Cys875 Enhancement of Ser831 phosphorylation,
facilitation of the associated increase in
AMPA receptor conductance and
endocytosis
GluA1 S-nitrosation in cells
overexpressing WT GluA1, but not
GluA1-C875S, following exposure to
NO donors or in HEK-nNOS cells
Selvakumar
et al., 2013
GluN2A Cys399 Down-regulation of NMDA receptor
activity and decrease of calcium influx
Exogenous and endogenous NO-related
species elicit S-nitrosation of NR2A
in vitro
Choi et al.,
2000; Kim
et al., 1999
GluN1 Cys744/Cys798 Regulation of calcium influx through the
NMDA receptor
S-nitrosation of GluN1 in cerebrocortical
cultures and nNOS-HEK cells under
hypoxic conditions
Takahashi et al.,
2007
PSD-95 Cys3/Cys5 Reduction of synaptic clustering in granule
cells of the cerebellum
S-nitrosation following exposure to
exogenous or endogenous NO, and in
WT mice, but not in nNOS−/− mice
Ho et al., 2011a
Serine
racemase
Cys113 Inhibition of enzyme activity and feedback
mechanism to decrease the presynaptic
formation of D-serine
S-nitrosation and enzyme inhibition
using NO donors in vitro
Mustafa et al.,
2007
RyR1 Cys3635 Increase of calcium release from the
endoplasmic reticulum
S-nitrosation of RyR1 following exposure
to a NO donor
Kakizawa et al.,
2012
HDAC2 Cys262/Cys274 Chromatin remodelling, dendritic growth
and branching, and the activation of
genes associated with cortical
development, regulating radial migration
of cortical neurons
Endogenous NO production by NOS,
but not in nNOS−/− animals, and NO
donors induces S-nitrosation of HDAC2
Nott et al.,
2013; Nott
et al., 2008
Cdk5 Cys83/Cys157 Contribution to NMDA-induced dendritic
spine loss and neuronal apoptosis caused
by amyloid-β damage
NO donors elicit Cdk5 activation;
S-nitrosation of Cdk5 in human brain
with Alzheimer’s disease
Qu et al., 2011
Drp1 Cys644 Dendritic spine loss and neurodegeneration
in Alzheimer’s disease
NO donors and endogenous
nNOS-derived NO induces Drp1
S-nitrosation
Cho et al., 2009
EGF
receptor
Cys166/Cys305 Negative regulation of NSC proliferation in
the SVZ by down-regulation of the
ERK/MAPK pathway
EGF receptor is S-nitrosated in vitro in
the presence of NO donors
Murillo-Carretero
et al., 2009
H-Ras Cys118 Alteration of the active centre
conformation, allowing a faster transition
from GDP- to GTP-binding state
NO donors activate WT H-Ras, but not
H-Ras NO-insensitive mutant
Lander et al.,
1997; Lander
et al., 1995
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NMDA receptor, while calcium entering the postsynaptic
neuron by other channels does not necessarily increase NO
production (Sattler et al., 1999). The importance of NO for
LTP triggered by activation of NMDA receptors was demon-
strated by several laboratories in the early 1990s, showing
that LTP was abolished when neurons were treated with
NOS inhibitors (Böhme et al., 1991; 1993; O’Dell et al., 1991;
Mizutani et al., 1993; Zhuo et al., 1993). The membrane-
impermeable scavenger of NO, haemoglobin, also blocks LTP
when applied extracellularly, suggesting that NO must be
released extracellularly to the synaptic cleft for the occur-
rence of LTP (O’Dell et al., 1991). Furthermore, mice lacking
only nNOS (O’Dell et al., 1994) or eNOS (Dinerman et al.,
1994) are capable of normal LTP, but, in the presence of NOS
inhibitors, LTP is reduced, suggesting that NO is important
for LTP in these knockout mice. Moreover, an impairment of
hippocampal LTP was observed in double-knockout mice for
nNOS and eNOS, and no further reduction of LTP was found
following the use of NOS inhibitors, demonstrating that NO
derived from both NOS is involved in LTP (Son et al., 1996).
However, in mature neurons of the neocortex of adult
animals, synaptic potentiation was reduced (over 42%) in
mice lacking nNOS (Dachtler et al., 2011), and LTP was com-
pletely abolished in double-knockout mice for nNOS and the
glutamate receptor subunit GluA1, but not in eNOS/GluA1
double-knockout mice. These findings suggest that nNOS-
derived NO and GluA1 subunit of the AMPA receptor are
required for experience-dependent plasticity in the neocortex
(Dachtler et al., 2011), without any contribution by eNOS.
The contribution of NO to LTP may also be through cGMP
production and PKG activation (Zhuo et al., 1994; Gallo and
Iadecola, 2011), but recent studies have shown that several
intracellular proteins involved in LTP and in AMPA receptor
trafficking can be S-nitrosated (see Tegeder et al., 2011;
Martínez-Ruiz et al., 2013), including NMDA receptor subu-
nits and proteins associated with AMPA receptor membrane
insertion and internalization.
AMPA receptor trafficking to the postsynaptic membrane
is fine-tuned by a variety of regulator and adaptor proteins.
Synaptic plasticity is mostly driven by GluA1/GluA2-
containing AMPA receptors being inserted into the mem-
brane after high-frequency stimulation, while after synaptic
strengthening a new equilibrium is achieved by the inser-
tion of GluA2/GluA3 receptors (Shi et al., 2001). Membrane
insertion of GluA1/GluA2 subunits is controlled by associa-
tion with N-ethyl-maleimide sensitive factor (NSF), and
S-nitrosation of Cys91 on the NSF protein was shown to
drive the surface expression of AMPA receptors containing
GluA2 subunits (Huang et al., 2005), by allowing the disso-
ciation of protein interacting with C α-kinase 1 from AMPA
receptors and favouring membrane expression (Sossa et al.,
2007). The surface expression of GluA1-containing AMPA
receptors is regulated by stargazin, which is physiologically
S-nitrosated on Cys3 (Selvakumar et al., 2009). Recently,
S-nitrosation of stargazin was also shown to mediate the
up-regulation of AMPA receptors in the nucleus accumbens
shell of cocaine-sensitized rats during withdrawal
(Selvakumar et al., 2014), which implicates S-nitrosation of
stargazin in the pathophysiology of addiction mechanisms
that involve up-regulation of membrane expression of
AMPA receptors.
The GluA1 subunit itself is also a target for S-nitrosation.
Cys875 may be modified following NO production triggered by
NMDA receptor activation by glutamate and thus enhance
phosphorylation of Ser831, resulting in an increase in channel
conductance (Selvakumar et al., 2013). In the same study,
nitrosation of Cys875 was also shown to facilitate binding of
AP2 protein and promote endocytosis of AMPA receptors
(Selvakumar et al., 2013).
S-nitrosation was also observed in NMDA receptor
GluN2A and GluN1 subunits, with implications for the activ-
ity and permeability of NMDA receptors and, thus, on post-
synaptic calcium influx. NMDA receptor GluN2 subunits are
coupled to nNOS by the PSD-95/Dlg/ZO-1 (PDZ) domains of
PSD-95, at the postsynaptic density (Christopherson et al.,
1999) and nitrosation of GluN2A Cys399 down-regulates
NMDA receptor activity and decreases calcium influx (Kim
et al., 1999; Choi et al., 2000). Moreover, following hypoxia
or stroke, GluN1 subunits appear nitrosated at the Cys744/
Cys798 pair, regulating calcium influx through the NMDA
receptor, decreasing neurotoxicity (Takahashi et al., 2007).
PSD-95 may also be regulated by S-nitrosation on Cys3/Cys5
(leading to reduced synaptic clustering); S-palmitoylation of
the same residues favours synaptic localization of PSD-95 (Ho
et al., 2011a). Furthermore, serine racemase, which converts
L-serine to D-serine, was shown to be influenced by NO.
D-Serine works as a co-agonist of NMDA receptors. Thus, in
the presence of NO, serine racemase is S-nitrosated at Cys113
and its enzymic activity is inhibited, creating a feedback
mechanism to decrease the presynaptic formation of
D-serine (Mustafa et al., 2007) after activation of glutamate
receptors, resulting in decreased signalling by the NMDA
receptor.
In the cerebellum, burst stimulation of the parallel fibres
triggers NO-dependent LTP in the parallel fibre-Purkinje cell
synapse (Namiki et al., 2005). NO was shown to increase
release of calcium from the endoplasmic reticulum via
S-nitrosation of Cys3635 in type 1 ryanodine receptors (RyR1),
thus triggering the calcium increase necessary for increasing
surface expression of AMPA receptors on the postsynaptic
membrane in Purkinje cells (Kakizawa et al., 2012).
In dorsal root ganglion (DRG) neurons, which are impor-
tant in nociception, NO inhibited the different types of
sodium channels via S-nitrosation of C-type DRG neurons
and consequently abolished sodium currents (Renganathan
et al., 2002). The blockage of sodium channels conductance
by a cGMP-independent mechanism could modulate the
excitability of these neurons and contribute to impaired
impulse in pathological conditions (Renganathan et al.,
2002). Moreover, NO was also shown to activate ATP-
sensitive potassium channels in large DRG neurons via
S-nitrosation of cysteine residues in the SUR1 subunit
(Kawano et al., 2009). Thus, by increasing the levels of NO,
the currents of the ATP-sensitive potassium channels could be
selectively enhanced even following a decrease in current
caused by painful-like nerve injury (Kawano et al., 2009).
Overall, S-nitrosation of proteins involved in synaptic
plasticity contributes to physiological receptor trafficking and
synapse activity, and also affords neuroprotection in injury
conditions. Recent evidence also indicates that S-nitrosation
may be involved in sensitization to some drugs of abuse such
as cocaine.
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S-nitrosation and formation of
new synapses
Synaptogenesis is the process that involves the modification
and elimination of existing synapses and the formation of
new synapses, resulting in the enhancement of learning and
memory formation, and can be modulated by NO. Despite
the relatively little information regarding its role in synaptic
rearrangement in adulthood, NO is mainly described as
a positive modulator of developmental synaptogenesis
(Roskams et al., 1994; Sunico et al., 2005). NO is required for
the refinement of retinal axonal connections (Wu et al., 1994)
and for the formation and maintenance of neuronal projec-
tions in the developing and regenerating olfactory system
(Roskams et al., 1994). Moreover, an increase in NOS expres-
sion seems to follow the axonal regenerative phase (Roskams
et al., 1994). In the hippocampus, the postsynaptic scaffold-
ing protein PSD-95 interacts with NOS and induces NO sig-
nalling, promoting synapse formation with nearby axons
during development (Nikonenko et al., 2008). Another study
with the NOS inhibitor Nω-nitro-L-arginine methyl ester dem-
onstrated the relevance of NO to the formation of synaptic
connections, as NOS inhibition decreased the immunoreac-
tivity of synapsin I and NADPH-diaphorase activity in the
prefrontal cortex, hippocampus and dorsal thalamus
(Sánchez-Islas and León-Olea, 2004). The close association
between nNOS, the nNOS adapter protein, C-terminal PDZ
domain ligand of nNOS, and synapsins (proteins associated
with presynaptic membrane vesicles and important for the
regulation of several functions including synaptic plasticity,
neurotransmitter release, synaptogenesis and neuronal pro-
liferation) seems to be responsible for this effect, and NO
deficiency affects learning and memory as a result of impair-
ment in synaptic connections (Sánchez-Islas and León-Olea,
2004).
More recently, some studies report the effect of NO on
synaptogenesis during adulthood. An increase in the immu-
noreactivity of synaptophysin was observed in the hip-
pocampal dentate gyrus, 72 h following epileptic seizures,
suggesting increased levels of synaptogenesis in this region.
Treatment with the selective nNOS inhibitor Nω-propyl-L-
arginine suppresses the increase in synaptogenesis, suggest-
ing that nNOS plays an important role in seizure generation
and in injury-induced synaptogenesis (Beamer et al., 2012).
Indeed, studies with in vivo models of epileptic seizures
showed a high rate of post-injury synaptic recovery in the
hippocampus (Nadler et al., 1980; Phelps et al., 1991). More-
over, in hippocampal slices, following anoxia/hypoglycaemia
stimuli, the postsynaptic NMDA receptors are activated, thus
increasing the calcium-induced release of NO, which stimu-
lates growth of presynaptic filopodia-like protrusions and
remodelling of presynaptic varicosities, contributing to syn-
aptogenesis (Nikonenko et al., 2003). On the other hand,
there are several reports showing a negative effect of NO on
motoneuron synaptogenesis (Sunico et al., 2005; 2010;
Moreno-López et al., 2011). During adulthood, NO produced
following injury to motoneuron axons is anti-synaptotrophic
as it leads to synapse detachment by cGMP-dependent
mechanisms, and is also anti-synaptogenic because of the
inhibition of synapse formation through a S-nitrosation-
mediated mechanism (Sunico et al., 2005). Indeed, a recovery
of synaptic coverage was observed following nNOS inhibi-
tion, suggesting that neuronal NO blocks the CNS restorative
events by a cGMP-dependent mechanism (Sunico et al.,
2005). Moreover, NO from nNOS inhibits the formation of
synapses necessary to recover normal functionality after
injury through an increase in S-nitrosation of proteins in
the synaptic bouton-like structures. However, the protein
targets of S-nitrosation remain to be identified (Sunico et al.,
2005).
Neurotrophins such as brain-derived neurotrophic factor
(BDNF) have a pivotal role in the differentiation, cell survival
and synapse formation in the CNS. Increasing BDNF levels
enhances axon arborization and synapse formation during
development, thus reversing the effect of NO, and suggesting
that the anti-synaptotrophic and anti-synaptogenic func-
tions of NO manifested following an injury might be due to
abnormal levels of neurotrophic factors (Alsina et al., 2001).
In neurons, BDNF triggers the synthesis of NO and subse-
quent S-nitrosation of two cysteine residues (Cys262 and
Cys274) of histone deacetylase 2 (HDAC2) in embryonic cor-
tical neurons. In turn, S-nitrosated HDAC2 promotes chro-
matin remodelling, dendritic growth and branching, and the
activation of genes associated with development (Nott et al.,
2008).
Regarding the involvement of S-nitrosation in synaptic
remodelling in neurodegenerative disorders, evidence of
cyclin-dependent kinase 5 (Cdk5) being a target for the effect
of NO in spine remodelling was found. S-nitrosation of Cys83
and Cys157 promote the activation of Cdk5, and this event
was further demonstrated to contribute to dendritic spine
loss caused by amyloid-β damage (Qu et al., 2011). Dynamin-
related protein 1 (Drp1) can also be S-nitrosated in Cys644 and
this modification has been linked to dendritic spine loss and
neurodegeneration in Alzheimer’s disease (Cho et al., 2009),
although phosphorylation of Drp1 in Ser616 has been
described in another study as a more likely modification that
promotes mitochondrial dysfunction and synaptic loss (Bossy
et al., 2010). Other proteins have been described to be
involved in neurodegenerative processes and this topic has
been recently reviewed by others (García-García et al., 2012;
Halloran et al., 2013; Nakamura et al., 2013).
More information is needed concerning the proteins
involved in synapse formation that are S-nitrosated, but
the relevance of this PTM is already becoming clear. The
identification of more proteins susceptible of being
S-nitrosated during the synaptogenic event as well as
identifying the cysteines modified is critical. As several
neurodegenerative diseases also affect the de novo formation
of synapses, targeting the critical residues could be of
therapeutic interest in limiting the progression and promot-
ing the recovery of neurons and neuronal function in these
pathologies.
S-nitrosation and neurogenesis
Neurogenesis is the process that involves the formation of
new neural cells from neural stem cells (NSC). Neurogenesis
occurs primarily during embryogenesis, when self-renewing
NSC are multipotent and give rise to the different neuroec-
BJPS-nitrosation and neuronal plasticity
British Journal of Pharmacology (2015) 172 1468–1478 1473
todermal lineages of the CNS (Gage et al., 1995). Nowadays,
it is commonly accepted that neurogenesis also occurs
throughout adult life. In the adult brain, there are two main
neurogenic niches where NSC reside and can be recruited to
give rise to new neurons: the subventricular zone in the wall
of the lateral ventricles and the subgranular zone in the
dentate gyrus of the hippocampus (see Gage and Temple,
2013). During adulthood, constitutive neurogenesis is
involved in neural turnover in the olfactory bulb, and in
learning and memory in the hippocampus respectively. The
neurogenic process comprises several steps including prolif-
eration, migration, survival and integration of the newly
formed neurons into the neuronal networks of the CNS.
Moreover, following certain conditions, such as neurodegen-
erative diseases and acute brain injuries, neurogenesis is
impaired and modulation of endogenous neurogenesis could
be a strategy to overcome these pathologies (Whitney et al.,
2009).
NO has been reported as a regulator of neurogenesis (see
Carreira et al., 2012). The role of NO in neurogenesis has been
described as neurogenic or antineurogenic in several studies.
Although some studies using NO donors and/or transgenic
animals describe NO as an antineurogenic molecule (Packer
et al., 2003; Moreno-López et al., 2004; Zhu et al., 2006;
Torroglosa et al., 2007), others show the potential of NO in
increasing different steps of neurogenesis, including prolif-
eration of NSC, migration and differentiation into new neu-
ronal cells (Cheng et al., 2003; Lu et al., 2003; Zhu et al., 2003;
Contestabile and Ciani, 2004; Covacu et al., 2006; Luo et al.,
2007; Carreira et al., 2010; 2013; Tegenge et al., 2010). Fur-
thermore, the amount and the source of NO are determining
factors for this dual role of NO. While NO derived from nNOS
has an inhibitory effect (Park et al., 2002; Sun et al., 2005;
Fritzen et al., 2007), NO produced by iNOS in response to an
injury, such as repeated seizures, ischemia or traumatic brain
injury, increases the proliferation rate of NSC and the
migration and differentiation into new neuronal cells (Reif
et al., 2004; Luo et al., 2007; Carreira et al., 2010).
Although most of the effects of NO in NSC proliferation
are mediated by the activation of ERK/MAPK and sGC/cGMP/
PKG pathways (Carreira et al., 2013), protein S-nitrosation
appears to be important for the activation and/or inhibition
of several proteins involved in the neurogenic process.
Several proteins susceptible to S-nitrosation are involved in
the control of cell proliferation. In the subventricular zone,
the EGF receptor is S-nitrosated following treatment with NO
donors and, thus, negatively regulates proliferation of NSC by
down-regulation of the ERK/MAPK pathway. Moreover, a
study with NO-insensitive mutants identified Cys166 and
Cys305 of the EGF receptor as the targets of S-nitrosation
(Murillo-Carretero et al., 2009). A more recent study reported
that NO was able to stimulate NSC proliferation by the acti-
vation of ERK/MAPK pathway, an effect that bypasses the EGF
receptor, suggesting that NO acts downstream of this receptor
in the modulation of cell proliferation by this pathway;
moreover, Ras, an element downstream of the EGF receptor,
appears likely to be the first target of NO (Carreira et al.,
2010). It has been described that NO triggers the activation of
H-Ras through S-nitrosation of Cys118, positioned near the
active centre; this modification alters the active centre con-
formation, allowing a faster transition from GDP- to GTP-
binding state (Lander et al., 1995; 1997). It remains to be
established whether S-nitrosation of Ras is directly correlated
to the up-regulation of neurogenesis by NO.
Some studies have attributed the down-regulation of
cAMP response element-binding protein (CREB) transcrip-
tional activity to the action of NO produced by nNOS, which
has an antiproliferative effect, both in the hippocampal
dentate gyrus and in the subventricular zone (Packer et al.,
2003; Moreno-López et al., 2004). CREB is activated by phos-
phorylation following an extracellular signal such as neuro-
trophins or neurotransmitters. CREB activity (but not CREB
itself) seems to be modulated by a NO-dependent signalling
pathway through S-nitrosation, as CREB activation is induced
by BDNF and is dependent on S-nitrosation of components in
the CREB DNA-binding complex. Thus, BDNF induces
S-nitrosation of proteins associated with the c-fos, nNOS and
VGF promoters and S-nitrosation of histone H3 (Riccio et al.,
2006), thus regulating CREB activity through S-nitrosation of
some of its binding partners. However, the molecular
pathway linking NO to down-regulation of CREB activity in
neurogenesis remains to be characterized.
HDAC2 is involved in neurogenesis, and the catalytic
function of HDAC2 was thought to be required only for adult
neurogenesis, but not for embryonic neurogenesis (Jawerka
et al., 2010). However, during development of the cortex,
S-nitrosation of HDAC2 at Cys262/Cys274 was observed follow-
ing the increase of NO production induced by BDNF, result-
ing in the regulation of the radial migration of neurons
during cortical development (Nott et al., 2013). S-nitrosation
of regulators of neuronal development is part of the physi-
ological signalling of embryogenesis.
As there is evidence showing that S-nitrosation is able to
modify a number of transcription factors and regulate gene
expression (see Sha and Marshall, 2012), it would be interest-
ing to investigate if their modification could affect neurogen-
esis and brain development. The identification of the cysteine
residues of proteins involved in the neurogenic process is
essential for the better understanding of the functional role of
the modifications.
Conclusion
NO has been widely recognized for its physiological functions
at the CNS level, which can be both beneficial and detrimen-
tal. Pathophysiological levels of NO, similar to those found in
neurodegenerative diseases, can be responsible for the pro-
gression of the disease by the S-nitrosation and other PTM of
several proteins (see Nakamura et al., 2013). Additionally, the
identification of the proteins that are abnormally S-nitrosated
in a particular neurodegenerative disorder will help to better
target those proteins and, thus, address their function or
signalling pathway in order to develop possible therapeutic
approaches. In this regard, the constant development of
more precise thiol redox proteomic techniques (Chouchani
et al., 2011; Izquierdo-Álvarez and Martínez-Ruiz, 2011;
Martínez-Acedo et al., 2012; López-Sánchez et al., 2014) and
their application to the field may be a valuable help in this
task.
In physiological conditions, S-nitrosation is involved in
the regulation of brain plasticity, as described in this review,
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including synaptic plasticity and formation of new neurons
and of new synapses. Here, we reviewed several proteins
modified by S-nitrosation of specific Cys residues that con-
tribute, directly or indirectly, to brain plasticity. Although
some of these proteins may be possible therapeutic targets for
increasing brain plasticity and, thus, ameliorate brain recov-
ery following a lesion of a chronic neurodegenerative state,
more studies are needed in order to better understand the
implications of S-nitrosation in the pathogenesis and future
therapeutic possibilities of neurodegenerative disorders.
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